In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline recommendations when multiple appropriate treatment options are available.
Elizabeth Wulff-Burchfield, MD
Articles by Elizabeth Wulff-Burchfield, MD
In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior adjuvant pembrolizumab or earlier immunotherapy exposure influences treatment selection in the metastatic setting.
In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination approaches in practice.
In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI combinations and, in select cases, TKI alone.
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.
In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist.
Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.
A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.
Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.
An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.
Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.
Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.
A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.
RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.
Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.
Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.
A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.
A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.
Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.
A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.
Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.
Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
